Literature DB >> 2172386

Development of microfusion techniques to generate human hybridomas.

S Foung1, S Perkins, K Kafadar, P Gessner, U Zimmermann.   

Abstract

The rarity of antigen-specific B cells in peripheral blood and lymphoid tissues is a major limitation in the production of human monoclonal antibodies. This has led to a requirement for techniques capable of fusing small numbers of cells and achieving a higher hybridoma formation efficiency than currently is possible. The approach used in these studies to generate human hybridomas is based on the observation that under hypo-osmolar conditions electric field induced cell fusion or electrofusion is facilitated. Electrofusion parameters have been defined in strongly hypo-osmolar solutions which have resulted in a hybridoma formation efficiency greater than 5 X 10(-3) under optimal conditions. Furthermore, this has been accomplished with total input B cells of 1-2 X 10(5). This is a ten-fold reduction in the required number of input B cells and is associated with a hybridoma formation efficiency at least equal to that achieved with a higher input B cell number. An important factor in the development of this microfusion technique appears to be the duration of exposure to the hypo-osmolar solution by B cells to be immortalized. Other parameters which may affect hybridoma yield include the electrical field strength used for cell alignment and membrane breakdown, ratio of human B cells to fusion partner, washing procedure, post-fusion incubation time, and the elimination of toxic molecules.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172386     DOI: 10.1016/0022-1759(90)90109-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

Review 1.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells.

Authors:  Marko Usaj; Katja Trontelj; Damijan Miklavcic; Masa Kanduser
Journal:  J Membr Biol       Date:  2010-07-14       Impact factor: 1.843

3.  Hypotonically induced changes in the plasma membrane of cultured mammalian cells.

Authors:  V L Sukhorukov; W M Arnold; U Zimmermann
Journal:  J Membr Biol       Date:  1993-02       Impact factor: 1.843

4.  Comparison of alkaline lysis with electroextraction and optimization of electric pulses to extract plasmid DNA from Escherichia coli.

Authors:  Saša Haberl; Marko Jarc; Aleš Strancar; Matjaž Peterka; Duša Hodžić; Damijan Miklavčič
Journal:  J Membr Biol       Date:  2013-07-06       Impact factor: 1.843

5.  Efficient production of IgG human monoclonal antibodies by lymphocytes stimulated by lipopolysaccharide, pokeweed mitogen, and interleukin 4.

Authors:  K Yoshinari; K Arai; H Kimura; K Matsumoto; Y Yamaguchi
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-06       Impact factor: 2.416

6.  Relationship between antibody productivity by activated human lymph node lymphocytes from lung cancer patients and lymphocyte subsets.

Authors:  K Yoshinari; K Arai; K Matsumoto; H Kimura
Journal:  Cytotechnology       Date:  1999-05       Impact factor: 2.058

Review 7.  Autophagy-dependent cell death.

Authors:  Donna Denton; Sharad Kumar
Journal:  Cell Death Differ       Date:  2018-12-19       Impact factor: 15.828

8.  Generation of human monoclonal antibodies recognising membranous antigens of the lung adenocarcinoma cell line A549 using an AMeX immunohistostaining method.

Authors:  K Yoshinari; H Kimura; K Arai; I Sugawara; K Noda; M Kihara; H Misaki; Y Yamaguchi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

Review 9.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.